ANTIBODIES STREAM
2nd Annual
Antibody-Drug Conjugates May 3 - 4
Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs. These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.
Day 1 | Day 2 | Download Brochure
THURSDAY, MAY 3
12:00 pm Registration
1:30 Chairperson’s Opening Remarks
Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.
» 1:40 Featured Speaker
Lessons Learned from the Clinic – T-DM1 and Beyond
John Lambert, Ph.D., CSO, ImmunoGen, Inc. (biography)
Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.
|
» 2:10 Featured Speaker
The Development of ADCs at Seattle Genetics
Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics (biography)
Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.
|
2:40 Sponsored Presentations (Opportunities Available)
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 SAR3419, a DM4-Loaded Antibody-Drug Conjuguate: Phase I Experience in B-Cell Lymphoma
Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis (biography)
4:30 Antibody-Drug Conjugates: Pre-Clinical Evaluation of a Novel Target
Andrew Simmons, Ph.D., Associate Director, Oncology, Takeda California (biography)
5:30-8:30 pm Recommended Dinner Short Course*
SC14 Antibody Conjugate Therapeutics: Potential and Challenges
*Separate registration required.
|
Day 1 | Day 2 | Download Brochure